You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Abbvie to continue manufacturing component for lymphoma drug
Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency
Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration
State of South Korean OTT Video: Subscription
Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.